Liposome mitoxantrone

Phase 2Small molecule

Liposome mitoxantrone is one of 63 small molecule programs targeting Acute Myeloid Leukemia (AML). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid Leukemia (AML)Not yet recruiting

Relapsed or RefractoryEnrolling by invitation

Acute Myeloid Leukemia (AML)Phase 2

Not yet recruiting

Relapsed or RefractoryPhase 1

Enrolling by invitation

Competition

Competitive Landscape

59 competitors in Relapsed or Refractory

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

5 2

Decadron

AAspen Global Incorporated

Phase 3

4 3

Copiktra

SSecuraBio

Phase 3

2 4

Venclexta

AbbVie

Phase 2

7 5

Fludara

Sanofi

Phase 2

7 6

Cytosar

Teva

Phase 2

6 7

Dacogen

Sun Pharmaceutical Industries, Inc.

Phase 2

5 8

Oncovin

Eli Lilly

Phase 2

3 9

Fludara

Sanofi

Phase 2

2 10

Cytoxan

BBaxter Healthcare Corporation

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Not yet recruiting

Acute Myeloid Leukemia (AML)

NCT07754799

Q4 2032

Phase 1Not yet recruiting

Acute Myeloid Leukemia (AML)

NCT07828535

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia (AML)2 trials

A Phase Ib Study of Liposomal Mitoxantrone Combined With Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit Patients With Acute Myeloid Leukemia

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07828535·30 enrolled

VISTA-AML- Venetoclax Intensity Selection Trial in AML: A Randomized Phase II Selection Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07754799·320 enrolled

Relapsed or Refractory1 trial

Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)

Enrolling by invitation·BBGI, China·Phase 1·NCT06499025·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Liposome mitoxantrone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liposome mitoxantrone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liposome mitoxantrone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BGI, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBGI, China

Liposome mitoxantrone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Q4 2032

Trials by Indication[1]

Acute Myeloid Leukemia (AML)2 trials

Relapsed or Refractory1 trial

References

Drug Info

Quick Facts

Related News